Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yosuke Minami

Showing results (101-110 of 103) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 103 results.
Eclinicalmedicine|February 19, 2025
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): long-term results of a multicentre, single-arm, phase 2 trialKazuyuki Shimada, Motoko Yamaguchi, Yachiyo Kuwatsuka, et al.
The New England Journal of Medicine|December 12, 2019
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor FailureTimothy P Hughes, Michael J Mauro, Jorge E Cortes, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 4, 2018
Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line TreatmentMasaya Okada, Jun Imagawa, Hideo Tanaka, et al.
Pageof 11

Showing results (101-110 of 103) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 103 results.
Eclinicalmedicine|February 19, 2025
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): long-term results of a multicentre, single-arm, phase 2 trialKazuyuki Shimada, Motoko Yamaguchi, Yachiyo Kuwatsuka, et al.
The New England Journal of Medicine|December 12, 2019
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor FailureTimothy P Hughes, Michael J Mauro, Jorge E Cortes, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 4, 2018
Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line TreatmentMasaya Okada, Jun Imagawa, Hideo Tanaka, et al.
Pageof 11